Treatment of Diabetic Autonomic Dysfunction

Foundational Management

The American Diabetes Association recommends achieving stable, near-normoglycemic control while avoiding extreme blood glucose fluctuations, as observational studies suggest neuropathic symptoms improve with optimization and avoidance of glycemic variability 1, 2
Intensive diabetes therapy retards cardiac autonomic neuropathy (CAN) development in type 1 diabetes, with Level A evidence 3, 4
Intensive multifactorial cardiovascular risk intervention retards CAN development and progression in type 2 diabetes, with Level B evidence 3, 4

The American Heart Association recommends implementing comprehensive non-pharmacological measures before initiating pharmacotherapy, as these form the foundation of orthostatic hypotension management 4, 5, 6
Discontinue or switch medications that exacerbate orthostatic hypotension, such as alpha-1 blockers, diuretics, vasodilators, and centrally-acting antihypertensives, rather than simply reducing doses 4, 7, 5
Increase fluid intake to 2-3 liters daily, unless contraindicated by heart failure 5, 6
Increase salt consumption to 6-9 grams daily, if not contraindicated 5, 6
Elevate the head of the bed by 10 degrees during sleep to prevent nocturnal polyuria and ameliorate nocturnal hypertension 6
Teach physical counter-maneuvers, such as leg crossing, squatting, stooping, and muscle tensing, during symptomatic episodes 5, 6
Use compression garments, such as waist-high compression stockings and abdominal binders, to reduce venous pooling 6
Recommend smaller, more frequent meals to reduce postprandial hypotension 5, 6
Acute water ingestion of ≥480 mL can provide temporary relief, with peak effect at 30 minutes 6

Midodrine is the preferred first-line pharmacological agent, with the strongest evidence base and FDA approval 3, 4, 5, 6
Dosing of midodrine should start at 2.5-5 mg three times daily, titrate up to 10 mg three times daily as needed 3, 4, 5, 6
Fludrocortisone is another first-choice agent, which can be used as monotherapy or in combination with midodrine 3, 4, 5, 6
Dosing of fludrocortisone should start at 0.05-0.1 mg daily, titrate to 0.1-0.3 mg daily based on response 3, 4, 6

For patients requiring concurrent hypertension treatment, use long-acting dihydropyridine calcium channel blockers or RAS inhibitors as first-line agents 7, 6
Avoid beta-blockers unless compelling indications exist 7, 6
Switch medications that worsen orthostatic hypotension to alternatives rather than dose-reducing 7, 6

Monitor supine blood pressure at every follow-up visit, as supine hypertension is the most important limiting factor and can cause end-organ damage 5, 6
Measure BP after 5 minutes lying/sitting, then at 1 and 3 minutes after standing 5, 6

Suspect gastroparesis in patients with erratic glucose control or upper GI symptoms without other identified cause 1, 2, 8
Exclude organic causes, such as gastric outlet obstruction or peptic ulcer disease, with esophagogastroduodenoscopy before diagnosing gastroparesis 8, 9
Gold standard diagnosis is scintigraphy of digestible solids at 15-minute intervals for 4 hours, or 13C octanoic acid breath test 9

Treat resting tachycardia with cardioselective beta-blockers without intrinsic sympathomimetic activity, such as metoprolol, nebivolol, or bisoprolol 3, 4, 5
Avoid beta-blockers in patients with orthostatic hypotension unless compelling indications exist 7, 6

Pregabalin, 100 mg three times daily, is an FDA-approved agent for the treatment of painful diabetic neuropathy 1, 2
Duloxetine, 60-120 mg daily, is another FDA-approved agent for the treatment of painful diabetic neuropathy 1, 2

Assess for autonomic neuropathy annually, starting at type 2 diabetes diagnosis and 5 years after type 1 diabetes diagnosis 8, 9
Screen for orthostatic hypotension by measuring BP after 5 minutes sitting/lying, then at 1 and 3 minutes after standing 5, 6
Perform comprehensive foot examination annually, with monofilament testing 1, 2